Top Page
ImExHS Limited
(Sydney:IME)
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
ImExHS Limited Business Overview & Revenue Model
ImExHS Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 26.57M | 19.67M | 17.12M | 13.37M | 10.91M | Gross Profit |
| 11.03M | 7.87M | 3.52M | 3.35M | 2.70M | EBIT |
| 626.59K | -2.59M | -2.42M | -3.14M | -2.31M | EBITDA |
| -908.26K | -1.26M | -744.21K | -3.01M | -1.30M | Net Income Common Stockholders |
| -2.63M | -4.19M | -3.04M | -4.70M | -3.62M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.07M | 2.36M | 1.91M | 4.19M | 10.80M | Total Assets |
| 21.81M | 22.65M | 20.99M | 25.01M | 20.80M | Total Debt |
| 1.19M | 1.29M | 1.12M | 2.40M | 1.70M | Net Debt |
| -882.73K | -1.07M | -794.80K | -1.79M | -9.10M | Total Liabilities |
| 7.33M | 6.67M | 5.09M | 8.36M | 5.27M | Stockholders Equity |
| 14.47M | 15.98M | 15.90M | 16.65M | 15.54M |
| Cash Flow | Free Cash Flow | |||
| -1.69M | 414.59K | -4.23M | -5.53M | -3.65M | Operating Cash Flow |
| -634.68K | 2.61M | -2.20M | -2.97M | -1.47M | Investing Cash Flow |
| -765.91K | -2.13M | -2.22M | -3.39M | -2.19M | Financing Cash Flow |
| 1.18M | -98.61K | 2.25M | -161.78K | 7.40M |
ImExHS Limited Technical Analysis
ImExHS Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$12.68B | 23.17 | 6.86% | 4.05% | 10.15% | 6.20% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
51 Neutral | AU$864.04M | 95.47 | 1.14% | 2.50% | 7.83% | ― | |
46 Neutral | AU$17.70M | ― | -17.24% | ― | 34.47% | 41.83% | |
| $5.63B | 1,072.73 | 0.52% | 2.23% | ― | ― | ||
48 Neutral | AU$290.28M | ― | -0.87% | 6.84% | 14.24% | -109.59% |
ImExHS Limited Corporate Events
ImExHS Limited has announced a change in the interests of its substantial holder, with a decrease in voting power from 14.13% to 12.25%. This change is primarily due to a dilution effect from a share placement and the issuance of shares under a conditional placement. The adjustments in shareholdings involve key stakeholders, including Digital Imaging Solutions S.A.S, German Arango, and Jorge Marin, which may impact the company’s shareholder dynamics and influence.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited announced a change in the director’s interest, specifically for German Arango, who is the controlling shareholder of Digital Imaging Solutions S.A.S. The change involves the acquisition of 175,810 nil price options and 328,572 fully paid ordinary shares, which were issued under the company’s Long-Term Incentive Plan and a Conditional Placement approved at the recent Annual General Meeting. This move reflects the company’s strategic efforts to align its leadership’s interests with long-term growth objectives, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited announced a change in the director’s interest, with Douglas Lingard acquiring additional securities. The acquisition includes 37,356 nil price options and 542,858 fully paid ordinary shares, reflecting a strategic move under the Long-Term Incentive Plan and Conditional Placement. This change is expected to impact the company’s stock and stakeholder interests positively.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest notice involving Carlos Jaime Palacio. The notice details the acquisition of 37,356 nil price options and 328,572 fully paid ordinary shares through direct and indirect interests, respectively. This change reflects the company’s ongoing efforts in corporate governance and aligns with its Long-Term Incentive Plan and Conditional Placement strategy approved at the recent Annual General Meeting.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest, specifically for Director Damian Banks. The changes involve both direct and indirect interests in securities, with acquisitions and disposals of fully paid ordinary shares and nil price options. This update reflects the company’s ongoing adjustments in its corporate governance and director’s shareholding structure, which may influence stakeholder perceptions and the company’s market positioning.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest, specifically involving Douglas Flynn. The change includes the acquisition and disposal of various securities, with Flynn acquiring 74,711 nil price options and additional fully paid ordinary shares through off-market transfers and conditional placements. This adjustment in Flynn’s holdings reflects strategic moves within the company’s governance and could potentially impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited has issued 2,857,146 new fully paid ordinary shares at A$0.35 each, raising A$1 million through a Conditional Placement. This move, announced on April 3, 2025, aligns with the company’s compliance with relevant provisions of the Corporations Act and reflects its strategic efforts to bolster financial resources, potentially impacting its operational capabilities and market positioning.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited has successfully completed a Conditional Placement, raising $1.0 million by issuing 2,857,146 new fully paid ordinary shares at A$0.35 per share to certain directors and their associated entities. This strategic move, approved at the recent Annual General Meeting, is expected to bolster the company’s financial position, potentially enhancing its market presence and operational capabilities in the medical imaging industry.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced the issuance of unquoted equity securities under its Long Term Incentive Plan. This includes options for non-executive directors, the CEO, and employees, totaling over 1.2 million securities. This move is part of the company’s strategy to incentivize and retain key personnel, potentially strengthening its market position and aligning the interests of its leadership with those of its stakeholders.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced the quotation of 2,857,146 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code IME, effective May 22, 2025. This move follows prior transactions and is part of the company’s strategic financial operations, potentially enhancing its market presence and providing liquidity options for stakeholders.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited held its 2025 Annual General Meeting, where shareholders voted on several resolutions, including the re-election of directors and the approval of options grants. The meeting also approved a 10% share placement capacity. These decisions are expected to impact the company’s governance and financial strategies, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited announced the successful deployment of its new software platform, Aquila+, which is AI-enabled and designed to enhance productivity, data security, and cost efficiency. Despite economic uncertainties, particularly in Latin America, the company remains unaffected by tariffs and is focused on expanding its market presence. The company has also addressed working capital pressures in its Radiology Services business by settling a long-standing debtor issue, allowing it to focus on growth.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited announced the quotation of 47,664 fully paid ordinary securities on the Australian Securities Exchange (ASX) with the issue date of May 9, 2025. This move signifies the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its operational dynamics and investor relations positively.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited has successfully completed its Share Purchase Plan (SPP), following a $1.5 million placement to institutional investors and a conditional $1.0 million placement to its directors. The SPP resulted in the issuance of 294,287 new shares at $0.35 each, aligning with the placement price, and these shares will rank equally with existing shares. This financial maneuver is expected to bolster IMEXHS’s market position and support its ongoing operations, potentially benefiting stakeholders by enhancing the company’s capital structure.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the interests of its director, Carlos Jaime Palacio, in the company’s securities. The change involves the exercise of nil price options, resulting in an increase in the number of ordinary shares directly held by Mr. Palacio. This adjustment reflects the company’s commitment to transparency and good corporate governance, as the securities held indirectly through family trusts are also disclosed, although Mr. Palacio does not control these entities.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has experienced a change in the interests of its substantial holders, as reported in a recent notice. The company’s voting power has shifted slightly, with the substantial holder’s voting power decreasing from 16.54% to 15.28% due to on-market trading and dilution from new share issuances. This change in voting power may impact the company’s governance and decision-making processes.
IMEXHS Limited reported a Q1 FY25 revenue of $7.1 million, marking a 1% increase compared to the previous corresponding period, with an 8% rise excluding a one-off sale. The company also saw a 16% growth in Annualized Recurring Revenue (ARR), reaching $31.4 million. The quarter highlighted the commercial launch of Aquila+, their next-generation radiology platform, now operational at eight sites, alongside securing new software contracts and a significant contract extension. The company raised $2.5 million through capital raising initiatives to support growth, with further fundraising efforts underway. These developments indicate a strategic focus on expanding their market presence and enhancing profitability in radiology services.
IMEXHS Limited has announced an extension of its Share Purchase Plan (SPP) offer period, moving the closing date from 2 May 2025 to 9 May 2025. This extension provides eligible shareholders in Australia, New Zealand, and Colombia additional time to participate in the SPP, potentially impacting the company’s capital structure and shareholder engagement positively.
ImExHS Limited has announced its Annual General Meeting (AGM) scheduled for May 19, 2025, at 11:00 am AEST, to be held both in person at Level 7, 32 Martin Place, Sydney, and virtually. Shareholders are encouraged to participate and vote on resolutions, which will be decided by poll. The company has provided online resources for accessing the Notice of Meeting and participating in the AGM, emphasizing the importance of shareholder engagement and voting.
IMEXHS Limited has opened a Share Purchase Plan (SPP) for eligible shareholders in Australia, New Zealand, and Colombia, allowing them to acquire up to A$30,000 worth of new shares at A$0.35 per share. The plan aims to raise up to A$1.0 million and is not underwritten, offering shareholders an optional opportunity to participate in the company’s growth following a recent A$2.5 million placement.
ImExHS Limited has announced the quotation of 4,285,712 new ordinary fully paid securities on the Australian Securities Exchange (ASX), effective April 14, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations.
IMEXHS Limited announced a correction to the Record Date for its Share Purchase Plan, now set for 7.00pm AEDT on Wednesday 2 April. This adjustment ensures accurate information for stakeholders participating in the plan, reflecting the company’s commitment to transparency and effective communication with its investors.
ImExHS Limited has announced a proposed issue of securities under a securities purchase plan, intending to issue up to 2,857,143 ordinary fully paid shares. This initiative aims to bolster the company’s financial position and support its strategic objectives, potentially enhancing its market presence and offering growth opportunities for stakeholders.
ImExHS Limited has announced a proposed issue of 4,285,712 ordinary fully paid securities, with the issue date set for April 14, 2025. This strategic move is likely aimed at raising capital to enhance the company’s operations and strengthen its market position, potentially impacting stakeholders by increasing the company’s financial flexibility and capacity for growth.
ImExHS Limited has announced a proposed issuance of 2,857,146 ordinary fully paid securities, scheduled for May 23, 2025. This move is part of a placement or other type of issue, aimed at raising capital to support the company’s operations and potentially strengthen its market position within the medical imaging sector.
IMEXHS Limited has successfully raised $2.5 million to support its growth initiatives, including the expansion of its AI-enabled software platform, Aquila+. The company is also in advanced negotiations for a significant radiology contract with a public hospital district in Bogota, Colombia. The capital raised will be used to provide working capital and drive sales growth, with strong support from institutional and sophisticated investors, as well as company directors. This financial boost positions IMEXHS to enhance its market presence and improve profitability in 2025.
ImExHS Limited announced a change in the director’s interest, with German Arango, the controlling shareholder of Digital Imaging Solutions S.A.S., experiencing a lapse of 49,173 options. This adjustment in securities does not affect the total number of shares held by Arango, indicating a stable position in the company’s ownership structure.
ImExHS Limited has announced a change in the director’s interest notice, specifically regarding Carlos Jaime Palacio. The notice details the acquisition of 26,683 ordinary shares by Mr. Palacio, valued at $10,035, as part of his compensation for the quarter ending 31 March 2025. This acquisition reflects the company’s practice of issuing shares in lieu of non-executive director fees, which may impact the company’s governance and shareholder structure.
ImExHS Limited announced a change in the director’s interest, with Douglas Lingard acquiring 26,683 ordinary shares. This acquisition was made in lieu of non-executive director fees for the quarter ending 31 March 2025, reflecting a strategic move to align director interests with company performance.
ImExHS Limited has announced a change in the director’s interest, specifically regarding Damian Banks, who has increased his direct holdings in the company by acquiring 26,683 ordinary shares. This acquisition was made in lieu of non-executive director fees for the quarter ending March 31, 2025, bringing his total direct holdings to 60,099 ordinary shares. This move reflects a strategic alignment of the director’s interests with the company’s performance and could signal confidence in the company’s future prospects.
ImExHS Limited has announced a change in the interest of its director, Douglas Flynn, in the company’s securities. The change involves the acquisition of 53,365 ordinary shares, increasing his direct holdings to 120,199 shares. This acquisition was made as part of a compensation arrangement, where shares were issued in lieu of non-executive director fees for the quarter ending March 31, 2025. This move reflects the company’s strategy to align director interests with shareholder value, potentially impacting its governance and stakeholder confidence.
ImExHS Limited announced the quotation of 140,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of April 2, 2025. This move is part of the company’s strategic efforts to strengthen its market presence and provide additional value to its stakeholders by expanding its financial base.
IMEXHS Limited has requested a trading halt on its securities as it prepares for a capital raising initiative. The halt will remain in effect until the company releases an announcement regarding the capital raising or until normal trading resumes on April 4, 2025. This move is aimed at facilitating the capital raising process, which could have implications for the company’s financial strategy and market positioning.
ImExHS Limited has released its corporate governance statement for the financial year ending December 31, 2024, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, detailing the roles and responsibilities of the board and management, the process for appointing directors, and the accountability of the company secretary. This announcement highlights ImExHS Limited’s commitment to transparency and compliance with governance standards, potentially reinforcing stakeholder confidence in the company’s management practices.
IMEXHS Limited has released its Corporate Governance Statement as of March 2025, detailing its adherence to the ASX Corporate Governance Council’s recommendations. The statement outlines the company’s governance practices, including the roles and responsibilities of the board and management, strategic direction, and oversight mechanisms. This release emphasizes the company’s commitment to maintaining transparency and accountability, potentially strengthening its position in the market and reassuring stakeholders of its governance standards.
IMEXHS Limited has completed the major software development of its new product, Aquila+, which is now operational in eight sites and being implemented for new contracts. Aquila+ aims to improve radiology workflow efficiency, radiologist productivity, and operational benefits through advanced AI-driven features, high security standards, and cost-effective multi-tenant architecture. The company has received ISO 27001 Certification for Aquila+ and has secured its installation in one of Compensar’s hospitals, with formal market launches in Latin America set for April 2025.
IMEXHS Limited has announced a change in the date of its Annual General Meeting (AGM), which will now be held on May 19, 2025, at its Sydney office. The deadline for director nominations has been extended to March 25, 2025. This adjustment provides stakeholders additional time for participation and nomination submissions, potentially impacting the company’s governance and strategic planning.